changing the paradigm of drug development
Monday, July 25, 2011
Transparency featured at BioPharma Physicians blog
http://www.biopharmphysicians.com/crowd-sourcing-in-clinical-development/
Sunday, July 24, 2011
NIH on Crowdsourcing: The Art and Science of Open Innovation
This one day (July 18th 2011) event organized by the NIH is now available for viewing
http://videocast.nih.gov/PastEvents.asp
http://videocast.nih.gov/PastEvents.asp
Sunday, July 17, 2011
Open-source start-up Transparency LS lands seed funding
CHICAGO -- Open-source drug development upstart Transparency Life Sciences has "raised a small seed round" of funding. It's using the funds to build an Internet presence, says Tomasz Sablinski, head of clinical development at private equity concern Celtic Therapeutics, in an interview at the recent DIA show. Sablinski also is founder of TLS.
New co-founders include Marc Foster, a biotech IT entrepreneur and president at tech startup catalyst Foster & Roberts, and Larry Steinman of Stanford University's Beckman Center for Molecular Medicine.
The Internet presence will be a space for like-minded open-source drug developers to create and work on projects. Sablinski says he plans to officially launch TLS in the next few months with one drug development pilot project and then add subsequent projects. His goal is a "robust portfolio" by year's end.
Sablinski has been the chief champion of TLS, advocating not just open-source software but drug development as a whole. He questions whether drug development can be a viable business without using open source, and whether Big Pharma is capable of making the transition.
TLS is "more on the trajectory of a web-based company than a biotech. And I'm looking for similarly fast ROI by being transparent," Sablinski says. He adds that other companies have signed on with TLS and that several partnerships are in the works. Among these joiners are "traditional and nontraditional companies in biopharma drug development."
Read more: Open-source start-up TLS lands seed funding - FierceBiotechIT http://www.fiercebiotechit.com/story/open-source-start-tls-lands-seed-funding/2011-07-04#ixzz1SNkstZea
Subscribe: http://www.fiercebiotechit.com/signup?sourceform=Viral-Tynt-FierceBiotechIT-FierceBiotechIT
New co-founders include Marc Foster, a biotech IT entrepreneur and president at tech startup catalyst Foster & Roberts, and Larry Steinman of Stanford University's Beckman Center for Molecular Medicine.
The Internet presence will be a space for like-minded open-source drug developers to create and work on projects. Sablinski says he plans to officially launch TLS in the next few months with one drug development pilot project and then add subsequent projects. His goal is a "robust portfolio" by year's end.
Sablinski has been the chief champion of TLS, advocating not just open-source software but drug development as a whole. He questions whether drug development can be a viable business without using open source, and whether Big Pharma is capable of making the transition.
TLS is "more on the trajectory of a web-based company than a biotech. And I'm looking for similarly fast ROI by being transparent," Sablinski says. He adds that other companies have signed on with TLS and that several partnerships are in the works. Among these joiners are "traditional and nontraditional companies in biopharma drug development."
Read more: Open-source start-up TLS lands seed funding - FierceBiotechIT http://www.fiercebiotechit.com/story/open-source-start-tls-lands-seed-funding/2011-07-04#ixzz1SNkstZea
Subscribe: http://www.fiercebiotechit.com/signup?sourceform=Viral-Tynt-FierceBiotechIT-FierceBiotechIT
Life Science Leaders article on Crowdsourcing Drug Development
This article (page 22) discusses the need of different models for clinical studies and features prominently the Transparency Life Sciences model.http://digital.lifescienceleadermag.com/link/lslead/2011/jul/1?s=0
“The obvious place to start is finding new clinical indications and
uses for generic drugs. We already know a lot about their modes of
actions and their safety profiles, and repurposing them for other indi-
cations has a higher probability of success than developing new or
novel drugs.”
Tomasz Sablinski, M.D., Ph.D., managing director at Celtic Therapeutics
“The obvious place to start is finding new clinical indications and
uses for generic drugs. We already know a lot about their modes of
actions and their safety profiles, and repurposing them for other indi-
cations has a higher probability of success than developing new or
novel drugs.”
Tomasz Sablinski, M.D., Ph.D., managing director at Celtic Therapeutics
Subscribe to:
Posts (Atom)